Need to keep on prime of the science and politics driving biotech in the present day? Join to get our biotech publication in your inbox.
Good morning. It’s a busy day for biotech information, let’s get proper to it.
The necessity-to-know this morning
- Merck, AstraZeneca, and Incyte reported earnings for the second quarter.
- Novo Nordisk lowered its gross sales and working revenue forecast for the remainder of 2025. The Danish pharma big additionally named a new CEO.
-
Outcomes from a Fulcrum Therapeutics examine counsel a tablet can deal with sickle cell illness, however specialists warning the drug’s impact was modest and extra information shall be have to show affected person profit.
- Apellis Prescription drugs received approval from the FDA to broaden the usage of its drug Empaveli to incorporate remedy for sufferers with C3 glomerulopathy, a uncommon kidney illness.
FDA now says Sarepta can ship remedy to younger sufferers
In a reversal, the Meals and Drug Administration yesterday cleared the way in which for Sarepta Therapeutics to renew shipments of its gene remedy for Duchenne muscular dystrophy to youthful sufferers who can stroll.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
